It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Safety

Adverse events were comparable between JAKAVI and BAT in both acute and chronic GvHD1

Commonly reported adverse events from the REACH2 trial
Commonly reported adverse events from the REACH3 trial

JAKAVI maintained a safety profile in SR GvHD consistent with over 10 years of
real-world experience in MF and PV1-3

Learn more about customizable dosing
Discover superior efficacy with JAKAVI
Explore the impact of GvHD
References
  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; January 2022.
  2. Zeiser R, von Bubnoff N, Butler J, et al; REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810.
  3. Zeiser R, Polverelli N, Ram R, et al; REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228-238.

This is an international website for JAKAVI® (ruxolitinib) and is intended for healthcare professionals outside of the United States. If you are a U.S. resident, please click here or on the U.S. Residents link on this page.

© 2024 Novartis Pharma AG. All rights reserved.
117343-2 6/22
Use of this website is subject to our Terms of Use.